Chairman Charles E. Grassley, right, and ranking member Sen. Ron Wyden are seen before a Senate Finance Committee on drug pricing in America on February 26, 2019. (Tom Williams/CQ Roll Call)
Both the House and the Senate have competing bills aimed at addressing the rising costs of prescription drugs, a legislative priority backed by President Donald Trump.
But what would these various proposals accomplish, and how likely is it they’ll be signed into law?
[jwp-video n=”1″]
Recent Stories
Congress’ wide age gap comes into focus
Stopgap funding bill’s hemp troubles aren’t over
A Massachusetts primary tests Democrats’ appetite to ‘change the culture’
Trump creates beef with ranchers over new import plan
White House ballroom construction can proceed, SCOTUS says
HHS seeks input on kids vaccination changes called for by Trump